Clinical significance of Smac/DIABLO expression in colorectal cancer

Kazuya Endo, Shunji Kohnoe, Akihiro Watanabe, Hideya Tashiro, Hisanobu Sakata, Masaru Morita, Yoshihiro Kakeji, Yoshihiko Maehara

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) is released by mitochondria in response to apoptotic stimuli and is thought to regulate apoptosis by antagonizing inhibitors of apoptosis proteins, which play an important role in sensitization of cancer cells to various therapeutic regimens. The expression of Smac/DIABLO has been demonstrated in various cancer cells, though little is known about its clinical significance with respect to colorectal cancer. The current study was designed to evaluate the relationship between prognosis and Smac/DIABLO expression by clinicopathological analysis of patients with colorectal cancer. Smac/DIABLO expression was evaluated using immunohistochemical staining in 121 consecutive patients with colorectal cancer and the relationship between Smac/DIABLO expression and clinicopathological factors was analyzed. Smac/DIABLO-positive expression was detected in 80 of the 121 patients (66%). The incidence of lymph node and distant metastasis in Smac/DIABLO-negative cancer was significantly higher than that in Smac/DIABLO-positive cancer (P=0.0004 and P=0.003, respectively). While univariate analysis showed that survival in patients with Smac/DIABLO-negative expression was significantly poorer than in Smac/DIABLO-positive cases (P<0.0001), Smac/DIABLO-negative expression was a prognostic indicator independent of Dukes' staging and lymph node metastasis by multivariate analysis. This study proposes that the decrease of Smac/DIABLO expression is an independent factor determining the poorer prognosis of patients with colorectal cancer.

Original languageEnglish
Pages (from-to)351-355
Number of pages5
JournalOncology reports
Volume21
Issue number2
DOIs
Publication statusPublished - Apr 23 2009

Fingerprint

Inhibitor of Apoptosis Proteins
Caspase Inhibitors
Colorectal Neoplasms
Carrier Proteins
Mitochondria
Neoplasms
Lymph Nodes
Neoplasm Metastasis
Survival Analysis

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Endo, K., Kohnoe, S., Watanabe, A., Tashiro, H., Sakata, H., Morita, M., ... Maehara, Y. (2009). Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncology reports, 21(2), 351-355. https://doi.org/10.3892/or_00000229

Clinical significance of Smac/DIABLO expression in colorectal cancer. / Endo, Kazuya; Kohnoe, Shunji; Watanabe, Akihiro; Tashiro, Hideya; Sakata, Hisanobu; Morita, Masaru; Kakeji, Yoshihiro; Maehara, Yoshihiko.

In: Oncology reports, Vol. 21, No. 2, 23.04.2009, p. 351-355.

Research output: Contribution to journalArticle

Endo, K, Kohnoe, S, Watanabe, A, Tashiro, H, Sakata, H, Morita, M, Kakeji, Y & Maehara, Y 2009, 'Clinical significance of Smac/DIABLO expression in colorectal cancer', Oncology reports, vol. 21, no. 2, pp. 351-355. https://doi.org/10.3892/or_00000229
Endo K, Kohnoe S, Watanabe A, Tashiro H, Sakata H, Morita M et al. Clinical significance of Smac/DIABLO expression in colorectal cancer. Oncology reports. 2009 Apr 23;21(2):351-355. https://doi.org/10.3892/or_00000229
Endo, Kazuya ; Kohnoe, Shunji ; Watanabe, Akihiro ; Tashiro, Hideya ; Sakata, Hisanobu ; Morita, Masaru ; Kakeji, Yoshihiro ; Maehara, Yoshihiko. / Clinical significance of Smac/DIABLO expression in colorectal cancer. In: Oncology reports. 2009 ; Vol. 21, No. 2. pp. 351-355.
@article{2263f916e00947afa8ec8094d17faf67,
title = "Clinical significance of Smac/DIABLO expression in colorectal cancer",
abstract = "Second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) is released by mitochondria in response to apoptotic stimuli and is thought to regulate apoptosis by antagonizing inhibitors of apoptosis proteins, which play an important role in sensitization of cancer cells to various therapeutic regimens. The expression of Smac/DIABLO has been demonstrated in various cancer cells, though little is known about its clinical significance with respect to colorectal cancer. The current study was designed to evaluate the relationship between prognosis and Smac/DIABLO expression by clinicopathological analysis of patients with colorectal cancer. Smac/DIABLO expression was evaluated using immunohistochemical staining in 121 consecutive patients with colorectal cancer and the relationship between Smac/DIABLO expression and clinicopathological factors was analyzed. Smac/DIABLO-positive expression was detected in 80 of the 121 patients (66{\%}). The incidence of lymph node and distant metastasis in Smac/DIABLO-negative cancer was significantly higher than that in Smac/DIABLO-positive cancer (P=0.0004 and P=0.003, respectively). While univariate analysis showed that survival in patients with Smac/DIABLO-negative expression was significantly poorer than in Smac/DIABLO-positive cases (P<0.0001), Smac/DIABLO-negative expression was a prognostic indicator independent of Dukes' staging and lymph node metastasis by multivariate analysis. This study proposes that the decrease of Smac/DIABLO expression is an independent factor determining the poorer prognosis of patients with colorectal cancer.",
author = "Kazuya Endo and Shunji Kohnoe and Akihiro Watanabe and Hideya Tashiro and Hisanobu Sakata and Masaru Morita and Yoshihiro Kakeji and Yoshihiko Maehara",
year = "2009",
month = "4",
day = "23",
doi = "10.3892/or_00000229",
language = "English",
volume = "21",
pages = "351--355",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - Clinical significance of Smac/DIABLO expression in colorectal cancer

AU - Endo, Kazuya

AU - Kohnoe, Shunji

AU - Watanabe, Akihiro

AU - Tashiro, Hideya

AU - Sakata, Hisanobu

AU - Morita, Masaru

AU - Kakeji, Yoshihiro

AU - Maehara, Yoshihiko

PY - 2009/4/23

Y1 - 2009/4/23

N2 - Second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) is released by mitochondria in response to apoptotic stimuli and is thought to regulate apoptosis by antagonizing inhibitors of apoptosis proteins, which play an important role in sensitization of cancer cells to various therapeutic regimens. The expression of Smac/DIABLO has been demonstrated in various cancer cells, though little is known about its clinical significance with respect to colorectal cancer. The current study was designed to evaluate the relationship between prognosis and Smac/DIABLO expression by clinicopathological analysis of patients with colorectal cancer. Smac/DIABLO expression was evaluated using immunohistochemical staining in 121 consecutive patients with colorectal cancer and the relationship between Smac/DIABLO expression and clinicopathological factors was analyzed. Smac/DIABLO-positive expression was detected in 80 of the 121 patients (66%). The incidence of lymph node and distant metastasis in Smac/DIABLO-negative cancer was significantly higher than that in Smac/DIABLO-positive cancer (P=0.0004 and P=0.003, respectively). While univariate analysis showed that survival in patients with Smac/DIABLO-negative expression was significantly poorer than in Smac/DIABLO-positive cases (P<0.0001), Smac/DIABLO-negative expression was a prognostic indicator independent of Dukes' staging and lymph node metastasis by multivariate analysis. This study proposes that the decrease of Smac/DIABLO expression is an independent factor determining the poorer prognosis of patients with colorectal cancer.

AB - Second mitochondria-derived activator of caspases/direct inhibitor of apoptosis-binding protein with low pI (Smac/DIABLO) is released by mitochondria in response to apoptotic stimuli and is thought to regulate apoptosis by antagonizing inhibitors of apoptosis proteins, which play an important role in sensitization of cancer cells to various therapeutic regimens. The expression of Smac/DIABLO has been demonstrated in various cancer cells, though little is known about its clinical significance with respect to colorectal cancer. The current study was designed to evaluate the relationship between prognosis and Smac/DIABLO expression by clinicopathological analysis of patients with colorectal cancer. Smac/DIABLO expression was evaluated using immunohistochemical staining in 121 consecutive patients with colorectal cancer and the relationship between Smac/DIABLO expression and clinicopathological factors was analyzed. Smac/DIABLO-positive expression was detected in 80 of the 121 patients (66%). The incidence of lymph node and distant metastasis in Smac/DIABLO-negative cancer was significantly higher than that in Smac/DIABLO-positive cancer (P=0.0004 and P=0.003, respectively). While univariate analysis showed that survival in patients with Smac/DIABLO-negative expression was significantly poorer than in Smac/DIABLO-positive cases (P<0.0001), Smac/DIABLO-negative expression was a prognostic indicator independent of Dukes' staging and lymph node metastasis by multivariate analysis. This study proposes that the decrease of Smac/DIABLO expression is an independent factor determining the poorer prognosis of patients with colorectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=62849124148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62849124148&partnerID=8YFLogxK

U2 - 10.3892/or_00000229

DO - 10.3892/or_00000229

M3 - Article

C2 - 19148507

AN - SCOPUS:62849124148

VL - 21

SP - 351

EP - 355

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 2

ER -